“…Though encompassing different brain activation paradigms, based on meta-analysis of standard pharmacological treatments (Delaveau et al, 2011;Ma, 2015), single ketamine administration in depression (Murrough et al, 2015;Reed et al, 2019) and in healthy subjects T A B L E 1 Participants demographic information with statistical differences at baseline, and clinical measures for both patient groups (ECT and ketamine) for baseline (TP1) and for after treatment (TP2; 24 to 72 hr after the fourth infusion of ketamine and after the last ECT session) , we hypothesized that treatment-related changes in neural activity would also occur in the larger corticolimbic-striatal face emotion processing network, including in striatal, medial prefrontal/ACC regions, and insula for negative stimuli, and increases in medial prefrontal/ACC regions for positive stimuli. Since ketamine and ECT have different molecular mechanisms of action, are subject to different side effects and may target different symptoms, we also expected that some neural effects would diverge at the systems level especially in regions involved in cognition and memory (Li et al, 2018;Perrin et al, 2012;Yrondi, Peran, Sauvaget, Schmitt, & Arbus, 2018 (Sackeim, 2001). To evaluate emotional processing within and across fast-acting therapies, 27 TRD patients received serial ketamine infusion and 17 patients received an index series of ECT using a nonrandomized naturalistic design.…”